Since the misregulation of NF-κB is associated with various diseases, including inflammation and cancers [4, 21, 22], the IKKβ inhibitor IMD-0354 has been investigated as an anticancer agent, and by suppressing NF-κB, a significant reduction in tumor size in breast cancer xenograft mice and a significant decrease in tumor cells and tumor size in pancreatic cancer xenograft mice have been reported [4, 22]. This evidence concerns the gene NFKB1 and neoplasm.